Yantai Innoe Biotechnology

Yantai Innoe Biotechnology is a clinical-stage biopharmaceutical company headquartered in Yantai, China, focused on developing next-generation biologics for metabolic diseases. The company utilizes a proprietary protein engineering platform to create long-acting multi-target agonists, specifically targeting GLP-1, GIP, and Glucagon receptors. Its lead program, INN-0101, is a triple agonist currently in Phase 2 clinical trials for obesity and type 2 diabetes, aiming to provide superior weight loss and glycemic control compared to existing therapies. Beyond metabolic health, Innoe is expanding its pipeline to address liver diseases such as NASH and other chronic conditions through innovative recombinant protein technologies. The company is supported by prominent Chinese venture capital firms and maintains state-of-the-art R&D and manufacturing facilities.